Novavax was particularly convincing in a new study for one age group. The following article reveals how good the results were and how the protection against omicron works:
Novavax only received approval from the European Medicines Agency (EMA) at the end of 2021. The first vaccinations in Germany should start at the end of February. The protein-based vaccine from the USA is considered a great hope for many vaccine skeptics who do not trust mRNA vaccines.
Novavax has recently provided good data in numerous studies. As echo24.de * reports, the effectiveness results from the latest series of tests are particularly convincing for one age group*. Protection against the omicron variant was also examined. *echo24.de is an offer from IPPEN.MEDIA.
